These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 10404594)
1. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594 [TBL] [Abstract][Full Text] [Related]
2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148 [TBL] [Abstract][Full Text] [Related]
3. The pp60c-Src inhibitor PP1 is non-competitive against ATP. Karni R; Mizrachi S; Reiss-Sklan E; Gazit A; Livnah O; Levitzki A FEBS Lett; 2003 Feb; 537(1-3):47-52. PubMed ID: 12606029 [TBL] [Abstract][Full Text] [Related]
4. Structure of human Fyn kinase domain complexed with staurosporine. Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058 [TBL] [Abstract][Full Text] [Related]
5. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583 [TBL] [Abstract][Full Text] [Related]
6. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs. Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402 [TBL] [Abstract][Full Text] [Related]
7. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778 [TBL] [Abstract][Full Text] [Related]
8. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Yamaguchi H; Hendrickson WA Nature; 1996 Dec; 384(6608):484-9. PubMed ID: 8945479 [TBL] [Abstract][Full Text] [Related]
9. Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding. Tong L; Warren TC; Lukas S; Schembri-King J; Betageri R; Proudfoot JR; Jakes S J Biol Chem; 1998 Aug; 273(32):20238-42. PubMed ID: 9685372 [TBL] [Abstract][Full Text] [Related]
10. Structural basis for selective inhibition of Src family kinases by PP1. Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133 [TBL] [Abstract][Full Text] [Related]
11. Structure of the regulatory domains of the Src-family tyrosine kinase Lck. Eck MJ; Atwell SK; Shoelson SE; Harrison SC Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222 [TBL] [Abstract][Full Text] [Related]
12. Structural investigation of the binding of a herpesviral protein to the SH3 domain of tyrosine kinase Lck. Schweimer K; Hoffmann S; Bauer F; Friedrich U; Kardinal C; Feller SM; Biesinger B; Sticht H Biochemistry; 2002 Apr; 41(16):5120-30. PubMed ID: 11955060 [TBL] [Abstract][Full Text] [Related]
13. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Krystal GW; DeBerry CS; Linnekin D; Litz J Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619 [TBL] [Abstract][Full Text] [Related]
14. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Eck MJ; Shoelson SE; Harrison SC Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435 [TBL] [Abstract][Full Text] [Related]
15. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495 [TBL] [Abstract][Full Text] [Related]
16. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases. Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305 [TBL] [Abstract][Full Text] [Related]
18. Discovery of thienopyridines as Src-family selective Lck inhibitors. Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410 [TBL] [Abstract][Full Text] [Related]
19. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Jacobs MD; Caron PR; Hare BJ Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071 [TBL] [Abstract][Full Text] [Related]
20. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. Lamers MB; Antson AA; Hubbard RE; Scott RK; Williams DH J Mol Biol; 1999 Jan; 285(2):713-25. PubMed ID: 9878439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]